Menu
Question:
What is the intent behind U0002? Is it true that it is reportable for in-house developed tests?
Answer:
HCPCS U0002 allows laboratories and healthcare facilities to bill CMS for validated, in-house developed COVID-19 tests. By code definition, the test must detect multiple types or subtypes; it should not be used for CDC.
| U0002 | 2019-nCoV Coronavirus, SARSCoV- 2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC |
This question was answered in an edition of our Laboratory Compliance Manager. For more hot topics relating to laboratory services, please visit our store or call us at 1.800.252.1578, ext. 2.
CPT® copyright 2021 American Medical Association (AMA). All rights reserved.
Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
CPT is a registered trademark of the American Medical Association.
Subscribe to receive our News, Insights, and Compliance Question of the Week delivered right to your inbox.
Address: 445 Minnesota Street, Suite 514
St. Paul, MN 55101
Phone: (800) 252-1578
Email: support@medlearnmedia.com
Hours: 9am – 5pm CT
Copyright © 2022 MedLearn Publishing. Powered by MedLearn Media.
